Abivax is trading up 4.38% at $95.05 on September 28, 2026, with no specific catalyst established. - The broad market is weaker, and the supplied market data does not explain the gain. - Searches found company updates and an analyst price-target cut from earlier in September, but no clear Abivax-specific announcement on September 28 linked to the move. - Current-session trading volume or activity details were unavailable in the sources reviewed.